Stock CATX PERSPECTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Perspective Therapeutics, Inc.

Equities

CATX

US46489V3024

Market Closed - Nyse
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
9.55 USD -7.28% Intraday chart for Perspective Therapeutics, Inc. -19.95% +137.56%
06-12 Sector Update: Health Care Stocks Ease Late Afternoon MT
06-12 Sector Update: Health Care Stocks Softer Wednesday Afternoon MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon
MT
Perspective Therapeutics to Join Russell 3000 Index on July 1
MT
Perspective Therapeutics to Reverse Split Common Shares
MT
Perspective Therapeutics Prices $80 Million Share, Warrant Offering
MT
Perspective Therapeutics Swings to Loss in Q1, Revenue Rises
MT
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry
CI
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study
MT
Perspective Therapeutics, Inc. Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb)VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
CI
Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.
CI
Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform
CI
Perspective Therapeutics, Inc. Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs
CI
Lantheus Holdings Signs Share Purchase, Licensing Deals With Perspective Therapeutics
MT
Perspective Therapeutics, Inc. Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability
CI
Perspective Therapeutics, Inc. entered into an asset purchase agreement to acquire Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc. for $8 million.
CI
Perspective Therapeutics Gains After Licensing Cancer Treatment from Mayo Clinc
MT
Perspective Therapeutics, Inc. Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment
CI
Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CATX Stock
  4. News Perspective Therapeutics, Inc.
  5. Highlights